top of page

2025 POSTER ABSTRACTS

(Download abstract list as PDF)
Abstract #
Abstract Title
POSTER SESSION 1: October 8 4:30-6:30 PM ET
NEALS 30TH ABSTRACT
1
RNS60 Protects Neuromuscular Junctions in the Diaphragm Muscle of TDP-43 Associated Amyotrophic Lateral Sclerosis
2
Presymptomatic gene expression changes in motor neurons in a large animal model of motor neuron degeneration
3
microRNA-206 is a reproducibly sensitive and specific plasma biomarker of amyotrophic lateral sclerosis
4
NfL in the NFL: A Prospective Longitudinal Study of Neurofilament Light Chain as a Biomarker of Neurological Injury in Professional Football Players.
5
Novel ESR-Based Blood Test for Early ALS Diagnosis Through SOD1 Structural Analysis
6
Phenotypic Drug Screening in Human iPSC-Derived Neurons Identifies Modifiers of Dipeptide Repeat-Induced Toxicity and TDP-43 Pathology in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia
7
Chloroviruses and ALS
8
Discovery and characterisation of a novel inhibitor of the Mitochondrial Permeability Transition Pore in preclinical models of ALS
9
ALS-associated circular RNA hsa_circ_0000119 forms a ribonucleoprotein complex enriched with proteins central to ALS pathophysiology
10
Investigation of Cortical Hyperexcitability in the Sporadic Form of TDP-43 Pathology Using High-Density Multielectrode Array System
11
Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and the Biomarker Impact of Calpain-2 Inhibition in a Preclinical Model of ALS
12
Exploratory Post Hoc Analysis of Neutrophil-to-Lymphocyte Ratio as a Novel Responsiveness Biomarker for Edaravone Oral Suspension-Treated Patients With Amyotrophic Lateral Sclerosis vs Untreated Propensity Score-Matched PRO-ACT Historical Placebo Controls
13
Electrical Impedance Myography Via the Myolex mScan as an ALS Disease Progression Biomarker: Early Results from the ElectricALS Study
14
Dysregulated RNA Transcripts as Blood Biomarkers of ALS
15
Incorporating Serum Neurofilament Light Chain into ALS Diagnostic Criteria
16
Neurofilament proteoforms in amyotrophic lateral sclerosis are different in cerebrospinal fluid and blood
17
An Exploration of Serum Neurofilament Light Chain and Rate of ALSFRS-R Decline
18
Longitudinal trajectories of Change of Neurofilament Light Chain in the Answer ALS Cohort
19
Neurofilament Light Chain Reflects Clinical and Genetic Heterogeneity in a Real-World ALS Cohort
20
Hypermetabolism is common among symptomatic and asymptomatic C9orf72 pathogenic variant carriers and is associated with elevated neurofilament light chain levels
21
Predicting ALS survival using combined ALSFRS-R slope and NfL: insights from the ALS/MND Natural History Consortium’s data and biofluid collection study.
22
Platelet Proteomics to Identify Novel Biomarkers and Mechanistic Insights in ALS
23
Characterizing Microbial Markers Predictive for ALS Onset and Progression
24
Access to ALS and FTD biospecimens via NINDS-supported biospecimen repository, BioSEND
25
The Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS)
26
Northeast Amyotrophic Lateral Sclerosis (NEALS) Biorepository
27
Design and Operationalization of the PREVENT ALL ALS Genetic Testing Sub-Study
28
The ANSWER ALS Foundation: Advancing ALS Research Through Strategic Collaboration and Innovation
29
ASSESS ALL ALS: A longitudinal, multi-modal natural history study to characterize ALS disease progression using on-site and remote cohorts
30
PREVENT ALL ALS: Design for a national ALS gene carrier natural history study
31
The Robert Packard Center for ALS Research: 25 Years of Funding Global Collaborative Pre-Clinical Research
33
Target ALS Multi-Center Human Postmortem Tissue Core
34
ALS cervical cord MRI metanalysis shows flattening of the cervical enlargement region.
35
Multicenter imaging study in ALS to demonstrate scalability and clinical trial readiness of multimodal MRI: Preliminary data
36
Correlation of Quantitative Susceptibility Mapping with Upper Motor Neuron Dysfunction, Motor Function, and Demographics in Patients with PLS and ALS
37
Toward Comprehensive Remote Assessment of ALS Patients: Combining Objective Digital Measures with Patient Reports of Problems
38
Reducing Sample Size and Duration of ALS Clinical Trials Using Objective Speech-Based Digital Biomarkers
39
Evaluating the Precision of Quantitative Voice Characteristics as Endpoints in ALS Clinical Trials
40
Leveraging Integrated Digital Infrastructure to Modernize Remote-Enabled ALS Research: Lessons from the ALL ALS study
41
ALS genetic risk predictions using Kolmogorov Arnold Networks
43
Quantifying Ambulation in ALS Using Wearable Sensor-Derived Digital Outcomes
44
Accelerating ALS Drug Approval using Digital Health Technologies: Findings from the ADDS 2025 ALS Workshop
45
Quantifying upper limb function in ALS using wearable sensors during short prescribed exercises
46
Design of Digitize ALL ALS: A Wearable Sensor Sub-Study in the ALL ALS Consortium
47
Simultaneous bimanual neural control of two cursors by person with tetraplegia with microelectrode arrays in bilateral precentral gyri.
48
Rationale for digital health technology assessments in FUNCtion ALS, a Phase 1/2 trial of TRCN-1023, an antisense oligonucleotide restoring UNC13A, in adult persons with Amyotrophic Lateral Sclerosis
49
Mobile EEG Meets Generative AI: Benchmarking a Conversational BCI Across ALS and Control Cohorts
50
NeuroCHARTS™: A Data-Driven Platform to Streamline Clinical Trial Recruitment
51
Facial Stimulus based Virtual Environment BCI for At Home Use in ALS
52
A multisensory evoked potential brain-computer interface for amyotrophic lateral sclerosis (ALS)
53
Monitoring Neural Correlates of Cognitive Decline in ALS
55
Investigating the Relationship Between Cervical Flexor Strength and Tongue Strength in Individuals with Amyotrophic Lateral Sclerosis: A Retrospective Review
56
Oral Health and Hygiene in ALS: An Unmet Clinical Need
57
Real time Upper Airway Visualization to Improve Tolerance and Adherence to Mechanical Insufflation-Exsufflation in ALS: A Case Study
58
Preliminary Results of Combined Respiratory Training to Improve Pulmonary and Cough Function in individuals with ALS
59
Toward Automated Cranial Nerve Exam (CNE): Deep Learning-Based Tongue Segmentation in ALS
60
Multimodal AI for ALS Bulbar Severity Tracking: A Task and Feature Optimization Approach
61
Evaluation of an augmented reality eye-tracking headset for communication in patients with ALS
62
Oral Secretion Scale (OSS) - A Multi-National Validated Clinimetric Scale for Assessing State of Secretion Management in NIV-treated ALS Patients Identifies Differences in Secretion Management Device and Medication Use According to Site of ALS Onset
63
The Presence of Constipation in Amyotrophic Lateral Sclerosis and Correlation with Disease Characteristics
64
Gastrointestinal Symptoms in ALS: Evidence for Enteric Nervous System Involvement and Clinical Implications
65
Evaluation of GI tolerance of milk protein- versus plant protein-based enteral nutrition formulas in people with amyotrophic lateral sclerosis (ALS): A multi-site retrospective study
66
Factors of Confidence and Regret in Feeding Tube Decision-Making for People Living with Amyotrophic Lateral Sclerosis
67
Feeding Tube Placement: An Interdisciplinary Approach
68
Is the MIND diet feasible for people living with ALS? A 7-week pilot study of an educational dietary intervention
69
Investigation of the Timing of Enteral Nutrition Initiation in patients with tracheostomy invasive ventilation (TIV)
71
Improving NIV Use in ALS: A Collaborative Approach to Enhancing Tolerability and Adherence
72
The Delta FVC: A potential clinical outcome measure to predict rate of ALS progression
73
A yogic breathing program to enhance quality of life in people with amyotrophic lateral sclerosis: A mixed-methods pilot study
74
Multicenter Prospective Validation of a Clinical Prediction Tool for Respiratory Insufficiency in ALS: The Pennsylvania Amyotrophic Lateral Sclerosis Cohort Study
75
Smartphone Application-Mediated, Supervised, At-Home Telespirometry Identifies Statistically Significant Differences in Erect and Supine Slow Vital Capacity and ALSFRS-R Decline as a Function of Non-invasive Ventilation Treatment Status in Multicenter, Prospective, Longitudinal, Observational Clinical Study [NCT05106569]
76
At-Home Telespirometry Identifies Significantly Slower Decline of ALS Functional Rating Scale-Revised Total Score but not Erect/Supine Slow Vital Capacity in Edaravone-Treated ALS Subjects Not Requiring Non-Invasive Ventilation [NCT05106569]
77
Assessment of Spirometry Testing Using a Mask for Patients With ALS
78
Smartphone Application-Mediated, Respiratory Therapist-Supervised, At-Home Telespirometry Erect/Supine Slow Vital Capacity Measurements in Subjects With ALS: Patient-Reported 5-Item Likert Scale Feasibility and Participation End-of-Study Outcomes Questionnaire Confirms Ease of Implementation and Identifies Per-Subject Benefits
79
Predictors of Pneumonia in Motor Neuron Disease: An Exploratory Retrospective Analysis
81
Thick Secretions in ALS: What Patients Say
82
Cognitive and Behavioral Impairment in ALS: Associations with Survival and Supportive Intervention Uptake
83
Depression as a Predictor of ALS Progression and Study Adherence
84
Loneliness in ALS: An Exploration of Communication and Mobility Factors
85
Development and Preliminary Validation of an ALS-Specific Fatigue Rating Scale
86
A Web-based Survey on Lower Urinary Tract Symptoms in Amyotrophic Lateral Sclerosis
87
Clinical Decision-Making in Amyotrophic Lateral Sclerosis Rehabilitation: A Physical Therapy Practice Pattern Survey
88
Caring for the Homebound Patient with ALS
89
Preliminary Outcomes of Early Neuromuscular Rehabilitation in SOD1 ALS Patients Receiving Tofersen: A 6-Month Observational Study
90
Impact of Assisted Foam Rolling on Lower Limb Performance in Advanced ALS: A Case Report
91
Design of a minimal neck brace for pALS with Dropped Head Syndrome
92
Perspectives of Persons Living with ALS: A Thematic Analysis Across Clinical and Psychosocial Domains
93
A Report on the Relationship Between ALS Diagnostic Delay and Depression/Anxiety Symptoms
94
Cognitive Compass: Guiding ALS Patient Care with Interdisciplinary Neuropsychology
95
Informants (Study Partners) in presymptomatic FTD/ALS Research: Highlighting uncharacterized and uncommunicated potential risks
96
Navigating Complex Conversations in ALS
97
Exploring Palliative Care Needs in Amyotrophic Lateral Sclerosis. Perspectives from Patients and Caregivers: A Scoping Review.
98
A Novel Exploration of Sexual Behavior and Intimacy in Amyotrophic Lateral Sclerosis: One-Year Study Update
135
Unprecedented Progression of fALS with SOD1 and PFN1 Mutations: A Novel Case Report
99
Characteristics and Disease Burden of People With Amyotrophic Lateral Sclerosis in a United States-Based Population: Analysis of Real-World Data
100
Primary Reasons for Emergency Room Visits and Discharge Dispositions in Patients with Amyotrophic Lateral Sclerosis (ALS) at the Massachusetts General Hospital
101
Exploring Pain Management Procedures for Musculoskeletal Issues in Patients with Amyotrophic Lateral Sclerosis (ALS): A Retrospective Chart Review
102
Tofersen-associated Radiculitis in SOD1-ALS Effectively Managed with IV but not IT Corticosteroid Administration
103
Radiological characterization of tofersen-associated myelitis: a case report
104
The VITALS Trial: Comparing the Impact of Video Integration to Traditional Amyotrophic Lateral Sclerosis Visit Communication on Patient and Caregiver Quality of Life
105
The Feasibility and Acceptability of Sharing Video Recordings of Amyotrophic Lateral Sclerosis Clinical Encounters With Patients and Their Caregivers: Pilot Randomized Clinical Trial
106
A Pilot Study of Remotely-Administered Cognitively-Based Compassion Training (CBCT®) for People Living with ALS (pALS) and their Care Partners
212
Examining IGFBP7 as a Potential Therapeutic Target in People with ALS
213
Advanced base and prime editing strategies to correct common ALS-causing SOD1 mutations
Anchor 1
Abstract #
Abstract Title
NEALS 30TH ABSTRACT
32
The Cures Collective: A Cross-Disease Movement to Transform the Neurodegenerative Landscape
54
Updated Validation Evidence for Clinical Bulbar Assessment Scale (CBAS)
107
Exploring and Boosting Hope in ALS
108
Diagnostic Journey in a United States-Based Population of People With Amyotrophic Lateral Sclerosis: Analysis of Real-World Data
109
Clinical Phenotype Predicts Amyotrophic Lateral Sclerosis (ALS) Prognosis More Accurately than Region of Onset: A Retrospective Time-to-Event Analysis
110
Characterizing Dietary Supplement Use Among Individuals with ALS
111
ALSUntangled Program
112
The Usability of a VR Serious Training Game for Empowering ALS Patients
113
Proportion of Parents and Grandparents among Adults with ALS in a Multidisciplinary ALS Center
114
Improving Attitudes Towards Palliative Care: A Quality Improvement Project
115
A Community-Informed Approach to Assessing the Needs of People Living with ALS and Their Care Partners
116
Exploring Predictive Genetic Testing Protocols Across Adult-Onset Neurodegenerative Conditions
117
Supporting People with ALS in Seeking Genetic Testing: Impact of an Online Educational Decision Tool
118
Amyotrophic lateral sclerosis estimated prevalence cases from 2022 to 2030, data from the National ALS Registry
119
Amyotrophic Lateral Sclerosis as a Multistep Process: a Population-based Study from the National ALS Registry
120
Place of death in patients with motor neuron disease and the association with comorbidities during the COVID-19 pandemic: a population-based analysis
121
Are Plateaus Common? A Multicenter Real-World Retrospective Analysis
122
Racial Disparities in ALS Diagnostic Delay: A Comparison Between Illinois and California
123
The incidence and prevalence of amyotrophic lateral sclerosis among people with diabetes mellitus are increasing in the United States
124
An Interactive Dashboard for Dynamic Individualized Prediction Models for Times-to-Event in ALS Clinical Milestones
125
Time-to-event analysis of clinical milestones in the ALS/MND Natural History Consortium Dataset
126
Design Language for Study-Specific Charts and Clinical Tools for ALS Patient Profiling
127
Documenting Financial Burden Concerns in an ALS Multidisciplinary Clinic
128
Provider Perspectives on Financial Burden in a Multidisciplinary ALS Clinic
130
Anti-IgLON5 disease, an Underrecognized Mimicker of Bulbar-Onset Motor Neuron Disease: A Case Series from Massachusetts General Hospital ALS Multidisciplinary Clinic
131
A Case of SPG-11 Associated Juvenile ALS with Thin Corpus Callosum
132
ClClinical Spectrum of FUS-Associated ALS: A Single-Center Experience from Turkey
133
Clinical Course of FUS-ALS: A Retrospective Analysis of Clinical and Genetic Modifiers
134
Clinical Manifestations and Disease Trajectory of C9orf72-Associated ALS Spectrum Disorders In A Single-Center Indian Cohort
136
Factors Contributing to Survival among Veterans with ALS: Results from the VA Spinal Cord Injuries & Disorders Registry
137
Complementing the Spinal Cord Injuries & Disorders Registry (SCIDR) with local clinical records to better understand factors affecting disease progression at one Veterans Affairs medical center
138
The Effects of Glucagon-Like Peptide-1 Receptor Agonists Medications on Amyotrophic Lateral Sclerosis
139
Riluzole and Edaravone in ALS: Examining Real-World Use and Discontinuation
140
Differential impact of riluzole use on incident versus prevalent cases in the ALS/MND Natural History Consortium Dataset
141
Evaluation of Long-Term Prognosis of Edaravone in ALS Patients: A Real-World Comparative Study Using SUNRISE Japan and JaCALS Registry Data
142
Safety Data Summarizing 3 Years of Radicava ORS® (Edaravone) Using Postmarketing Pharmacovigilance From United States-based Patients With Amyotrophic Lateral Sclerosis
143
Understanding the use of Patient-Reported Outcome Measures in Primary Lateral Sclerosis: Insights from a Clinical Setting
144
Startle Reflex in Primary Lateral Sclerosis (PLS): A Comparison with Amyotrophic Lateral Sclerosis (ALS)
145
Exploring mobility patterns in three individuals with primary lateral sclerosis using smartphone-based digital phenotyping
146
Discovery of novel phosphosites in hSOD1-G37R preclinical models correlating with the efficacy of Borsantrazole, a novel edaravone analogue
147
Introducing Borsantrazole: A trifunctional boron-based pyrazole increases survival and delays disease onset in the SOD1-G37R mouse model of ALS
148
NU-9 treatment reduces the levels of mitochondrial DNA in the plasma of TAR4/4 sporadic ALS model with TDP-43 pathology
149
NU-9, in combination with other FDA-approved drugs, have better outcomes in models of TDP-43 pathology
150
Talineuren (TLN): A GM1-Loaded Nanoliposomal Therapeutic Targeting Mitochondrial Dysfunction and Proteostasis in ALS
151
ACE-2223, a novel oral small molecule for non genetically modified ALS, treats both gain- and loss-of-function TDP-43 pathology, extends survival and decreases NfL in vivo and has a favorable preclinical safety profile
152
Baseline characteristics and analysis of misfolded SOD1 target levels in a Phase 2 proof-of-concept study to evaluate the human antibody AP-101 in sporadic ALS and genetically determined SOD1-ALS
153
Preclinical Characterization of NUZ-001: A Brain-Penetrant Small Molecule that Reduces TDP-43 Aggregation in ALS Models
154
Engaging Diverse Voices, Shaping Trials: Integrating Patients and Caregivers into ALS Clinical Trial Design
155
Accelerating Study Start-up in Two Multi-Site Intermediate-Size Expanded Access Protocols Through a Collaborative Approach of a Comprehensive Academic Research Organization
156
Voice Recording Adherence in ALS: A Comparison of In-Clinic and At-Home Assessments
157
From Awareness to Enrollment: Navigating Patient Challenges to Improve Access to ALS Clinical Trials
158
Leveraging External Controls from PRO-ACT for Exploratory Efficacy Assessment in Early-Phase ALS Trials
159
Adverse Events: Disease Progression vs Reversible Effects in ALS
160
Leveraging Artificial Intelligence and Machine Learning for Extraction of Laboratory Reports
161
The NeuroPRO™ People-Reported Outcomes Platform, from Concept to Implementation: A Year in Review
162
Development and Validation of the Amyotrophic Lateral Sclerosis-Health Index (ALS-HI), a Novel, Regulatory-Grade, Patient-Reported Outcome Measure
163
Optimizing Trial Success: Key Staffing Considerations for Platform Trials
164
Enhancing ALS Trial Efficiency with Plasma NfL and Digital Twins
165
Optimizing Investigational Product Distribution in Clinical Trials: A Predictive Platform for Inventory and Delivery Management
166
Comprehensive Profiling and Collaborative Integration to Unveil ALS Mechanisms
167
Target ALS Natural History Study in a Global ALS Population
168
Clinical Trial Readiness: Using the FTD Disorders Registry to Identify FTD-ALS Participants for Research
169
Advancing EDC Systems with AI-Driven User Assistance via Azure-OpenAI Integration
170
ALL ALS Consortium: A Centralized Participant-Interest Form and Patient Navigation Workflow to Increase Recruitment and Remote Participation
171
Integrating Lived Experience: A Framework for Patient Advisory Boards in ALS Research
172
Variability of ALSFRS-R scores using multiple evaluators in the HEALEY ALS Platform Trial
173
Dual Coordination Centers role in ALL ALS Consortium: A Success Story, Not Too Many Cooks in the Kitchen
174
Legal and Regulatory Framework for Data Sharing
175
Efficient Site Contracting Enables Accelerated Study Start-Up of Two Multi-site Intermediate-Size Expanded Access Protocols
176
Utilizing Global Unique Identifiers for Data Deduplication and Extension of Longitudinal Datasets
177
Integrated Assessment of Function and Survival in ALS Trials: Comparative Evaluation of Rank-Based and Joint-Model Approaches in the HEALEY Platform
178
Enabling AI-Driven Research in ALS/MND through Data Standardization and Harmonization
179
A Comparison of Baseline Clinical Characteristics Between Decentralized and Institutionally-Enrolled Participants in the CNM-Au8 EAP04 Study
180
Neural Repair Reagent ALT001 Can Efficiently Treat Amyotrophic Lateral Sclerosis (ALS), From Bench to Clinic
181
Tofersen further slows ALS progression in a slowly progressive Glu101Lys family
183
A Phase I/IIa study with Mitochondrial Uncoupler MP101 once daily Oral Micro-Doses, Significantly Lowers NfL in the Cerebrospinal Fluid in Sporadic Amyotrophic Lateral Sclerosis Participants within 14-Days
184
A Phase 1/2, Multicenter Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Patients with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
185
FUNCtion ALS: A Phase 1/2 trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of TRCN-1023, an antisense oligonucleotide restoring UNC13A, in adult persons with Amyotrophic Lateral Sclerosis
186
SARM1 inhibitor LY3873862 as neuroprotective treatment in ALS: Design of a proof-of-concept trial regimen in the HEALEY ALS Platform Trial
187
Safety, Tolerability, and Pharmacokinetics of ATH-1105 in Healthy Volunteers
188
Phase 2a Topline Clinical Results Evaluating Neurophysiological and Functional Measures in SPG302-treated ALS Participants
189
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis
191
A Planned Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with ALS
192
Pridopidine exerts neuroprotective effects through the activation of the Sigma-1 receptor (S1R) by modulating ER stress in iPSC-derived neural progenitor cells
193
Protocol for A Duke University Pilot Trial Investigating the Safety and Efficacy of Microbiota Transplant Therapy (MTT) in People Living with Amyotrophic Lateral Sclerosis
194
Impact of Intrathecal delivery of INS1202 AAV9-SOD1-shRNA on hallmarks of neurodegeneration in a murine disease model of ALS and a patient-derived in vitro model.
195
Neuropathological characterization of anti-sense oligonucleotide treated Amyotrophic Lateral Sclerosis
196
Clinical Development of LTX-001, a small-molecule GLS1 inhibitor for the treatment for ALS
197
Clinical Development of LTX-002, an ASO for the treatment for ALS
199
DAZALS: A Phase 2, Randomized Controlled Trial of Dazucorilant, a Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis
200
PARAGON: A Phase 3, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial with an Open Label Extension Evaluating PrimeC in Amyotrophic Lateral Sclerosis
201
Patient-Centered Drug Development: Addressing Liquid Formulations and Enteral Administration Considerations in PRO-101
202
The CALM Study: Controlling ALS Motor Neuron Excitability Through Multi-Site Direct Current Stimulation.
203
ANQUR, the First-in-Human Phase 1 study of QRL-201 in ALS Advances to Dose-Range Finding using a Novel Population Pharmacokinetic Analysis
204
QRL-101 - PHASE 1 STUDIES EVALUATING SAFETY AND PHARMACODYNAMICS OF A KCNQ2/3 MODULATOR IN HEALTHY VOLUNTEERS & NEXT STEPS FOR DEVELOPMENT IN ALS
205
NADALS Basket Trial: Drug Repurposing with baricitinib, an FDA-approved JAK inhibitor, in ALS patients
206
RESTORE-ALS: A Ph3, Randomized, DB, Pb-Controlled Trial in Early Symptomatic Participants on Stable Background Therapy to Reduce Mortality and Clinical Worsening Morbidity Events in ALS
207
Cross-Regimen Analysis of CNM-Au8® 30 mg Demonstrated a Significant Survival Benefit Over Long-Term Follow-Up Compared to Regimen A in the HEALEY ALS Platform Trial
208
Comprehensive Responder Analysis with MN-166 in ALS trials
209
ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments
210
ACT for ALS EAPs by the Numbers
211
Development of LTX-002, a novel ASO for the treatment of ALS
212
Examining IGFBP7 as a Potential Therapeutic Target in People with ALS
213
Advanced base and prime editing strategies to correct common ALS-causing SOD1 mutations
POSTER SESSION 2: October 9 4:20-6:20 PM ET
Anchor 2

POSTER AWARDS

Basic Science Abstract Award

The Basic Science Abstract Award will be given to an outstanding abstract poster presentation focused on basic science. 

Clinical Investigation Abstract Award

The Clinical Investigation Abstract Award will be given to an exceptional abstract poster presenter focused on clinical investigation. 

UMN Achievement Award

The seventh annual UMN Achievement Award will be given to two abstracts focusing on PLS/UMN research. The UMN Achievement Award is supported by the Spastic Paraplegia Foundation (SPF) to promote UMN research and recognize those who contribute significantly to this field. 

SCIENCE HIGHLIGHTS

Science Symposium Presentation

Up to 2 abstract submissions focusing on sporadic ALS will be selected for 10-minute presentations during the Science Symposium portion of our conference.

Vials_edited.jpg

Lightening Science Talks

Up to 12 abstract submissions will be selected for 3-minute presentations during the conference.

  • LinkedIn
  • Twitter
  • Facebook
bottom of page